If you loved our Explainer on Cell and Gene Therapy, you'll love this new summarised version. This short report takes you through the key BIA member companies working in the AMR space, and explains the cutting-edge work taking place in the UK.
ARC has launched Motherlabs Oxford, a new purpose-built life sciences accelerator space at its ARC Oxford campus, expanding its early-stage laboratory offering in response to sustained demand across the sector.
In this blog, Emily Klein, Senior Policy and Public Affairs Executive at BIA, explores the hidden, wide-ranging impacts and costs of rare diseases to society and the wider economy in the UK.
Poolbeg Pharma (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology.
The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.
